JAMA NetworkTreatment with Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients with Cancer

Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial

The rates of grades 2, 3, 4, and 5 toxic effects were 14.2%, 4.2%, 0%, and 0.3%, respectively, in this population-based phase 2 nonrandomized clinical trial of 381 patients with oligometastatic or oligoprogressive disease that was designed to capture toxic effects prospectively as the primary end point.